Topics

"A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder" Drugs and Medication Database

08:34 EST 10th December 2019 | BioPortfolio

Here are the most relevant "A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder" Drugs and Medications that we have found in our database.

More Information about "A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder" on BioPortfolio

We have published hundreds of A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder news stories on BioPortfolio along with dozens of A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Clinical Trials and PubMed Articles about A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Companies in our database. You can also find out about relevant A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Drugs and Medications on this site too.

Showing "Study Safety Activity Eculizumab Pediatric Participants With Relapsing" Drugs and Medications, all 6

Possibly Relevant

Ultomiris [alexion pharmaceuticals inc.]

These highlights do not include all the information needed to use ULTOMIRIS™ safely and effectively. See full prescribing information for ULTOMIRIS. ULTOMIRIS™ (ravulizumab-cwvz) injection, for intravenous useInitial U.S. Approval: 2018

Teriflunomide [amneal pharmaceuticals llc]

These highlights do not include all the information needed to use TERIFLUNOMIDE TABLETS safely and effectively. See full prescribing information for TERIFLUNOMIDE TABLETS.  TERIFLUNOMIDE tablets, for oral use Initial U.S. Approval: 2012

Aubagio [genzyme corp.]

These highlights do not include all the information needed to use AUBAGIO safely and effectively. See full prescribing information for AUBAGIO. AUBAGIO (teriflunomide) tablets, for oral use Initial U.S. Approval: 2012

Tecfidera [biogen inc.]

These highlights do not include all the information needed to use TECFIDERA safely and effectively. See full prescribing information for TECFIDERA.TECFIDERA (dimethyl fumarate) delayed-release capsules, for oral useInitial U.S. Approval: 2013

Rebif [emd serono, inc.]

These highlights do not include all the information needed to use REBIF safely and effectively. See full prescribing information for REBIF. REBIF (interferon beta-1a), for subcutaneous injectionInitial U.S. Approval: 1996

Avonex [biogen inc.]

These highlights do not include all the information needed to use AVONEX safely and effectively. See full prescribing information for AVONEX.AVONEX (interferon beta-1a) injection, for intramuscular injectionInitial U.S. Approval: 1996



Quick Search